News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Immune Design Corporation Announces Treatment Of First Patient In Phase 1 Clinical Trial Of ID-G305 Cancer Immunotherapy Agent


2/27/2014 9:25:31 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SEATTLE and SAN FRANCISCO, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced treatment of the first patient in a Phase 1 clinical trial of ID-G305, a cancer immunotherapy investigational agent from the company's GLAASTM platform.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES